Observational studyJournal of pediatric gastroenterology and nutrition2026
Fecal calprotectin and other biomarkers are not prospectively associated with food protein-induced allergic proctocolitis.
Observational study in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosis and Management of Food Protein-Induced Allergic Proctocolitis.Current gastroenterology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesDiagnosis of food protein-induced allergic proctocolitis (FPIAP) is challenging due to the lack of noninvasive biomarkers. We evaluated fecal calprotectin, eosinophil-derived neurotoxin (EDN), and zonulin as potential biomarkers for diagnosing FPIAP, while also examining normal ranges in healthy infants under 12 months.
methodsWe analyzed 214 stool samples from 115 infants (63 with clinically diagnosed FPIAP) over the first year of life from a large prospective observational cohort. We examined the range for each biomarker in infants over time and compared biomarker concentrations in infants with and without FPIAP using linear mixed-effects modeling. We also compared biomarker concentrations to existing 16S rRNA microbiome profiles using MaAsLin2.
resultsConcentrations of calprotectin, EDN, and zonulin were not associated with FPIAP at the time of diagnosis (p = 0.81, p = 0.74, p = 0.24, nor longitudinally (p = 0.356, p = 0.0791, p = 0.333). Calprotectin was found to decrease significantly over the first 12 months of life for both groups (p < 0.001), while EDN and zonulin did not significantly change (p = 0.903, p = 0.043). There was no associated dysbiosis or microbial signature with any of the three biomarkers.
conclusionConcentrations of calprotectin, EDN, and zonulin were not associated with clinically diagnosed FPIAP in our cohort. Very high levels of calprotectin are noted in early infancy in asymptomatic healthy infants, and we provide normal ranges across the first year of life for all three biomarkers. This study does not support the use of fecal calprotectin, EDN, or zonulin for diagnosis of FPIAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.